| 1 minute

Concept Life Sciences Acquires Aquila BioMedical

Concept Life Sciences (Concept), announced they have acquired Aquila BioMedical (Aquila), an innovative pre-clinical contract research organisation with expertise in immuno-oncology, immunology and multiplex histology.

Aquila develop therapeutics for oncology, biomarker discovery and target expression, with services covering a wide range of in vitro and in vivo proof-of-concept studies. The acquisition will be a significant addition to the range of integrated services Concept provide as an integrated drug discovery, development and analytical services company.

To read the full article, click here.

Back to News

Do you have news for the Scottish Life Sciences Community?

Submit Your Own News